Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10373656" target="_blank" >RIV/00216208:11130/17:10373656 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/17:10373656

Výsledek na webu

<a href="https://doi.org/10.1182/blood-2016-07-726307" target="_blank" >https://doi.org/10.1182/blood-2016-07-726307</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1182/blood-2016-07-726307" target="_blank" >10.1182/blood-2016-07-726307</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Popis výsledku v původním jazyce

A fully-standardized EuroFlow 8-color antibody panel and laboratory procedure was stepwise designed to measure minimal residual disease (MRD) in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) patients with a sensitivity of &lt;= 10(-25), comparable to real-time quantitative polymerase chain reaction (RQ-PCR)-based MRD detection via antigen-receptor rearrangements. Leukocyte markers and the corresponding antibodies and fluorochromes were selected based on their contribution in separating BCP-ALL cells from normal/regenerating BCP cells in multidimensional principal component analyses. After 5 multicenter design-test-evaluate-redesign phases with a total of 319 BCP-ALL patients at diagnosis, two 8-color antibody tubes were selected, which allowed separation between normal and malignant BCP cells in 99% of studied patients. These 2 tubes were tested with a new erythrocyte bulk-lysis protocol allowing acquisition of high cell numbers in 377 bone marrow follow-up samples of 178 BCP-ALL patients. Comparison with RQ-PCR-based MRD data showed a clear positive relation between the percentage concordant cases and the number of cells acquired. For those samples with &gt; 4 million cells acquired, concordant results were obtained in 93% of samples. Most discordances were clarified upon high-throughput sequencing of antigen-receptor rearrangements and blind multicenter reanalysis of flow cytometric data, resulting in an unprecedented concordance of 98% (97% for samples withMRD &lt; 0.01%). In conclusion, the fully standardized EuroFlow BCP-ALLMRD strategy is applicable in &gt; 98% of patients with sensitivities at least similar toRQ-PCR (&lt;= 10(-25)), if sufficient cells (&gt; 4310 6, preferablymore) are evaluated.

Název v anglickém jazyce

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Popis výsledku anglicky

A fully-standardized EuroFlow 8-color antibody panel and laboratory procedure was stepwise designed to measure minimal residual disease (MRD) in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) patients with a sensitivity of &lt;= 10(-25), comparable to real-time quantitative polymerase chain reaction (RQ-PCR)-based MRD detection via antigen-receptor rearrangements. Leukocyte markers and the corresponding antibodies and fluorochromes were selected based on their contribution in separating BCP-ALL cells from normal/regenerating BCP cells in multidimensional principal component analyses. After 5 multicenter design-test-evaluate-redesign phases with a total of 319 BCP-ALL patients at diagnosis, two 8-color antibody tubes were selected, which allowed separation between normal and malignant BCP cells in 99% of studied patients. These 2 tubes were tested with a new erythrocyte bulk-lysis protocol allowing acquisition of high cell numbers in 377 bone marrow follow-up samples of 178 BCP-ALL patients. Comparison with RQ-PCR-based MRD data showed a clear positive relation between the percentage concordant cases and the number of cells acquired. For those samples with &gt; 4 million cells acquired, concordant results were obtained in 93% of samples. Most discordances were clarified upon high-throughput sequencing of antigen-receptor rearrangements and blind multicenter reanalysis of flow cytometric data, resulting in an unprecedented concordance of 98% (97% for samples withMRD &lt; 0.01%). In conclusion, the fully standardized EuroFlow BCP-ALLMRD strategy is applicable in &gt; 98% of patients with sensitivities at least similar toRQ-PCR (&lt;= 10(-25)), if sufficient cells (&gt; 4310 6, preferablymore) are evaluated.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood

ISSN

0006-4971

e-ISSN

—

Svazek periodika

129

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

347-357

Kód UT WoS článku

000396529800012

EID výsledku v databázi Scopus

2-s2.0-85018677964